Research on the Risk Warning Model and Prevention Strategies for Acute Kidney Injury Associated With Cyclosporine Based on Explainable Deep Neural Networks and Therapeutic Drug Monitoring
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 1,200
- 试验地点
- 1
- 主要终点
- AKI
研究概览
简要总结
In this study, the investigators will focus on hospitalized patients using cyclosporine and develop an acute kidney injury risk prediction model through in-depth analysis of electronic medical record data, employing interpretable deep learning methods. This model aims to provide timely decision-making support for clinicians regarding prevention and treatment. Compared to traditional machine learning models, deep neural network models can extract deeper features from complex medical data and perform more precise pattern recognition, thereby improving the accuracy and reliability of predictions. By developing a prediction tool based on interpretable deep learning models, the investigators will be able to better assess the association between the use of CNI-class immunosuppressants and acute kidney injury, explore targeted prevention strategies, and offer more accurate prediction and intervention guidance for clinicians. Additionally, this study has significant socioeconomic benefits and promising prospects for application and promotion.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •During hospitalization, tacrolimus or cyclosporine was used, and therapeutic drug monitoring was conducted according to standard procedures.
- •Aged 18 years or older at the time of admission.
- •Length of hospital stay > 48 hours.
- •At least 2 serum creatinine tests were conducted during hospitalization.
排除标准
- •Chronic kidney disease stage 5 was achieved before admission.
- •Incomplete clinical data.
- •Serum creatinine levels were consistently below 40 mmol/L during hospitalization.
结局指标
主要结局
AKI
时间窗: From January 2020 to December 2023
Acute kidney injury occurred in hospitalized patients treated with cyclosporine
次要结局
未报告次要终点
研究者
Xiao Li,MD
Associate professor of pharmacy
Qianfoshan Hospital
